September 14, 2018
Merck Sharp & Dohme Corp. has told the U.S. Supreme Court that "smoking gun" evidence from the U.S. Food and Drug Administration should sink a Third Circuit decision reviving multidistrict litigation over the company's alleged failure to warn about a risk of femoral fractures from its osteoporosis drug Fosamax.
July 17, 2018
The tsunami of litigation over the nation's deadly opioid crisis will continue to keep attorneys riveted as the parties work toward trial dates next year. And after a string of losses for patients who claim that Bayer failed to warn of its blood thinner Xarelto's bleeding risks, attorneys are looking to see if they can find a winning argument. Here are the product liability cases attorneys will be keeping an eye on for the rest of 2018.
June 29, 2018
On a U.S. Supreme Court with a recent retirement and a recusal, Merck's appeal of a Third Circuit decision reviving multidistrict litigation over the drug company's alleged failure to warn about femoral fracture risk from osteoporosis drug Fosamax could result in a 4-4 tie, experts said.
June 28, 2018
The U.S. Supreme Court on Thursday agreed to consider a Third Circuit decision that revived multidistrict litigation over Merck's alleged failure to warn about a risk of femoral fractures from its osteoporosis drug Fosamax.
June 11, 2018
Merck has told the U.S. Supreme Court that a brief by the U.S. solicitor general bolsters its bid to reverse a Third Circuit decision reviving multidistrict litigation over its alleged failure to warn about a risk of femoral fractures from its osteoporosis drug Fosamax.
June 06, 2018
Fosamax users on Tuesday urged the U.S. Supreme Court not to hear Merck's appeal of a Third Circuit decision reviving multidistrict litigation over the pharmaceutical giant's alleged failure to warn about its osteoporosis drug, saying that the case doesn't meet the court's usual standard for review.